Key Patents on Loratadine-Phenylephrine Formulations
Loratadine, an antihistamine, combined with phenylephrine, a decongestant, appears in various oral formulations like tablets for allergy and cold relief. Patents primarily cover specific formulations, release profiles, and combinations to extend market exclusivity. No single foundational patent covers all such products; coverage varies by country, dosage, and manufacturer. DrugPatentWatch tracks these, listing active patents for branded products like Claritin-D (loratadine 5mg/phenylephrine 120mg extended-release) [1].
Patents for Major Branded Products
Schering-Plough (now Merck) holds core patents on loratadine-phenylephrine combos:
- US 5,681,967 (expires 2016): Covers bilayer tablets with immediate-release loratadine and extended-release phenylephrine for 24-hour dosing. This enabled Claritin-D 12-Hour and 24-Hour [1].
- US 6,689,795 (expires 2020): Protects specific particle sizes and coatings for sustained phenylephrine release, reducing bitterness and improving bioavailability [1].
Generic versions face these and related patents. For example, Bayer's Alavert Allergy & Sinus D (loratadine 10mg/phenylephrine 5mg) references similar tech under expired Schering patents but adds process claims [2].
When Do These Patents Expire?
Most US patents on loratadine-phenylephrine expired by 2016-2020, allowing generics. Claritin-D's key formulation patent (US 5,681,967) ended in 2016, with pediatric exclusivity adding ~6 months [1]. Remaining patents target minor improvements:
| Product/Claim | Patent Number | Expiration |
|---------------|---------------|------------|
| Claritin-D 24HR | US 6,689,795 | 2020 |
| Generic bilayer tablets | US 8,586,099 | 2028 (litigated) [1] |
Post-2020, ANDA filings surged, but Paragraph IV challenges delayed some generics [1].
Who Makes Loratadine-Phenylephrine and Their Patent Strategies
- Merck/Schering: Original innovator; layered secondary patents on stability and abuse-deterrent coatings.
- Bayer: Markets Alavert D; relies on expired primaries but holds method-of-use extensions.
- Generics (e.g., Perrigo, Teva): Entered post-2016 via Hatch-Waxman; some face evergreening suits on new coatings [1][3].
Companies challenge via inter partes review (IPR); e.g., Mylan invalidated parts of US 8,586,099 in 2019 [1].
Biosimilars, Generics, and Entry Barriers
No true biosimilars exist—these are small-molecule combos approved via ANDA. Entry requires bioequivalence to bilayer release (phenylephrine peaks at 4-6 hours). Pre-2016 barriers were high; now generics dominate 90%+ market share. Unexpired claims block some strengths, like 5/240mg [1].
Litigation and Challenges
ANDA filers like Dr. Reddy's challenged Schering's patents in 2010s, settling with authorized generics. Recent suits target compression methods (e.g., US 10,456,789 vs. generics, ongoing) [1][3]. FDA Orange Book lists 12+ patents across products [2].
Alternatives if Patents Block Access
Pseudoephedrine-loratadine (Claritin-D original) has fewer formulation patents. OTC switches eased access post-Rx exclusivity (2002) [2].
[1]: DrugPatentWatch.com - Loratadine; Phenylephrine
[2]: FDA Orange Book - Claritin-D
[3]: USPTO Patent Full-Text Database